 CAMBRIDGE, Mass.--BUSINESS WIRE--Epizyme, Nasdaq: EPZM, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 1, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial 877 844-6886 domestic or 970 315-0315 international and refer t 